Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

How to Qualify Container Closure Systems for Intended Use, Part 2: Choosing the Right Components for Container Closure Systems

Author(s):  Vaughn Stacey R, Radwick Allison

Issue:  Jan/Feb 2020 - Volume 24, Number 1
View All Articles in Issue

Page(s):  14-19

How to Qualify Container Closure Systems for Intended Use, Part 2: Choosing the Right Components for Container Closure Systems Page 1
How to Qualify Container Closure Systems for Intended Use, Part 2: Choosing the Right Components for Container Closure Systems Page 2
How to Qualify Container Closure Systems for Intended Use, Part 2: Choosing the Right Components for Container Closure Systems Page 3
How to Qualify Container Closure Systems for Intended Use, Part 2: Choosing the Right Components for Container Closure Systems Page 4
How to Qualify Container Closure Systems for Intended Use, Part 2: Choosing the Right Components for Container Closure Systems Page 5
How to Qualify Container Closure Systems for Intended Use, Part 2: Choosing the Right Components for Container Closure Systems Page 6

Download in electronic PDF format for $75

Abstract:  The U.S. Food and Drug Administration regulates outsourcing facilities with the same stringency they apply towards drug manufacturers. This means that outsourcing facilities, who must navigate the changing regulatory landscape to achieve and maintain 503B status, must now focus on qualifying container closure systems for their intended use. This article, the second in a two-part series, examines component selection and methods for demonstrating that the container closure system will protect and maintain the quality of the compounded drug and ensure that the compounded drug can be safely administered to a patient.

Related Keywords: outsourcing facilities, container closure system qualification, drug packaging, U.S. Food and Drug Administration, FDA, injectable dosage forms, compounded sterile preparations, suitability, compatibility, safety, performance, testing methods, stability

Related Categories: LEGAL, PACKAGING, PARENTERALS, STERILE PREPARATIONS, QUALITY CONTROL, UNITED STATES PHARMACOPEIA CONVENTIONS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
How to Qualify Container Closure Systems for Intended Use, Part 1
Kim Amy A
, Gehrmann Matthew R, McCaw James, McAndrew T Page
Nov/Dec 2019
Pg. 454-461

How to Qualify Container Closure Systems for Intended Use, Part 2: Choosing the Right Components for Container Closure Systems
Vaughn Stacey R
, Radwick Allison
Jan/Feb 2020
Pg. 14-19

Basics of Sterile Compounding: Intravenous Admixture Preparation Considerations, Part 10: Packaging and Container-closure Issues
Allen Loyd V Jr
Jul/Aug 2021
Pg. 311-317

Basics of Sterile Compounding: Sterile Product Packaging and Delivery Systems
Akers Michael J
Nov/Dec 2015
Pg. 491-500

Quality Control: How to Produce a Well-closed Sealed Vial in a Regulated CGMP Environment: Part 2
Higgins Doral (Neal) O
, Prudom Melanie J, Summers Amy
Sep/Oct 2021
Pg. 389-395

In-use Stability of Ceftaroline Fosamil in Elastomeric Home Infusion Systems and MINI-BAG Plus Containers
Bhattacharya Sisir
, Parekh Satish, Dedhiya Mahendra
Sep/Oct 2015
Pg. 432-436

Errata - How to Qualify Container Closure Systems for Intended Use, Part 1 - IJPC 23(6) 454-461
Jan/Feb 2020
Pg. 86-87

View Sample
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Miller David G
May/Jun 2014
Pg. 208

PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

Quality Control: How to Produce a Well-closed Sealed Vial in a Regulated CGMP Environment: Part 1
Higgins Doral (Neal) O
, Prudom Melanie J, Summers Amy
Jul/Aug 2021
Pg. 298-302

Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
Jul/Aug 2016
Pg. 351

View Sample
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Miller David G
Jul/Aug 2015
Pg. 303-305

U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
Nov/Dec 2015
Pg. 487-488

IACP's Continuing Support of Compounding Pharmacists: Letter to the FDA Concerning 503B Outsourcing Facilities
Miller David G
Mar/Apr 2014
Pg. 117-118

Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management
Soni Abhishek
, Gowthamarajan Kuppusamy, Radhakrishnan Arun
Mar/Apr 2018
Pg. 108-121

Basics of Sterile Compounding: Biopharmaceutics of Injectable Dosage Forms
Akers Michael J
Jan/Feb 2017
Pg. 47-56

U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Snow Stephen T
, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Jan/Feb 2019
Pg. 32-33

Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
Jul/Aug 2020
Pg. 296-297

U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Yoch Doug
Mar/Apr 2017
Pg. 95-102

Child-safety Containers/Devices and Compounding
Allen Loyd V Jr
Sep/Oct 2017
Pg. 364-370

Return to Top